Uzbekistan Pharmaceutical Country Report 9M 2019

Uzbekistan Pharmaceutical Country Report 9M 2019

Brief Summary

The current Report uncovers the 9M 2019 business trends of the pharmaceutical market of the Republic of Uzbekistan, overviews its healthcare system, portrays its epidemiology and demographics. It also depicts pharma regulation features in Uzbekistan including a step-by-step process of the marketing authorization. It provides insight into the country’s socio-political development since independence, describes recent economic trends and gives an economic forecast for the next 3 years.

The Report is intended for industry executives, decision-makers, sales & marketing, and market access managers and other stakeholders. "Uzbekistan Pharmaceutical Country Report 9M 2019" will be useful for top-managers, business owners, consultants and other stakeholders of the Life Sciences industry, who are analyzing, planning to enter or invest in the Uzbek pharma and/or healthcare market.

The Report covers the 2012-2018 full-year data and 9M 2019 data for the pharmaceutical market and provides a forecast for the period of 2019-2022.

Series: Pharmaceutical Market Country Reports
Country: Uzbekistan
Data years: 2013-2018; 9M 2019
Format: .pdf
Additional files: .xlsx, .pptx
Price: EUR 500 EUR 300
Contents + Supply Chain Scheme: Download
Purchase single report, EUR 300: Purchase
Purchase the series (8 in 1), EUR 1,600: Purchase Request invoice

Political development of Uzbekistan in 2019

The process of reformation and liberalization of Uzbekistan, which had started in 2016, continued in 2019. Among the most important events of the year was the introduction of private land ownership in July 2019. Moreover, the construction boom began in the country - the old buildings were demolished, while much new housing and commercial real estate were built. Also, Uzbekistan reopened its doors to foreign and exile journalists in 2019. Another significant event was the closing of Jaslyk Prison, where human rights activists and ex-inmates alleged that torture was widespread.

During 2019, steps have been taken to develop the political system by increasing the role and importance of parties and deputies. On December 22, the first round of the Parliamentary elections under the new electoral law took place in the Republic of Uzbekistan. For the first time in the history of the country, during the election campaign, there were public debates among leaders and activists of participating parties, as well as among other candidates.

Uzbekistan became the country of the year that achieved the most progress in 2019, according to the British magazine The Economist. The editors believe that the country has become "much less oppressive" – primarily thanks to the liberal reforms carried out by President Mirziyoyev. According to The Economist, Uzbekistan still has a long way to go, but this year "no other country has come so far."

Economy of Uzbekistan in 2019

Real GDP growth in Uzbekistan accelerated to 5.7% in 9M 2019 from 4.9% in the same period a year ago, supported by a surge in investment growth that was financed by substantial increases in directed lending to state-owned enterprises.

In the reporting period, the share of industry in the GDP of Uzbekistan increased from 25.4% to 29.2%. Exports increased by 45.0% YoY in USD terms in 9M 2019, and imports by 33.0%, reflecting trade liberalization policies.

Average CPI decelerated to 14.1% in 9M 2019 from 18.2% during the same period in 2018. This stems mostly from slower growth in food prices, which has compensated for an increase in services inflation. Minimum wages, pensions, and allowances were increased by 10% on August 1, 2019.

Dashboard. Uzbekistan's Real GDP and GDP growth rates + Uzbekistani Sum exhange rates (avg)(Sources: IMF, Central Bank of Uzbekistan)

The economy is predicted to grow by 5.5% in 2019 and 6.0% in 2020, driven by further expansion of fixed investment, helped by rapid credit expansion and foreign direct investment facilitated by the government’s policies. Downside risks include a slowdown in the economies of trading partners and a continued credit surge, which may ignite inflationary pressures.

Trends of the pharmaceutical market of Uzbekistan in 2019

Market structure

As of 1 October 2019, there were 9,737 medicines registered in Uzbekistan and 73% of them had a foreign origin. Also, foreign companies registered 83% of all medical devices in the country and 95% of all medical equipment.

Dashboard. Shares of Local and Foreign Foreign Pharma Products Registered in Uzbekistan (as on 01/10/2019) Source: UPharma Consulting, the Ministry of Health of the Republic of Uzbekistan)

According to the Ministry of Health of Uzbekistan, local production is able to cover 24% of needed volumes of medicines in tablet forms, 20% - in powder forms, 33% - in capsule forms, 80% - in solution forms, and only 4% - in gel forms.

Uzbek companies can cover 91% of medicines needs in anesthesiology and transfusiology. At the same time, local companies have fragile positions in hematology (6.5%), immunology (7.5%), toxicology (2.6%), and obstetrics and gynecology (1.6%). Local production of antitumor drugs and diagnostic tools is almost absent in Uzbekistan.

Local pharmaceutical manufacturers

There were 162 licenses for conducting pharmaceutical activities issued in Uzbekistan in 2019, including 90 for the production of drugs, 61 for the production of medical devices, and 11, which produce both drugs and medical devices. Most companies (70%) operated in Tashkent city and its region. The remaining enterprises were unevenly distributed in other Uzbekistan regions. Most of the enterprises of the industry has been limited to the production of drugs of simple formula products.

  • The biggest local manufacturers: Jurabek Laboratories, Merrymed Farm and Remedy Group.
  • The most competitive international companies on the market: Berlin-Chemie/Menarini, KRKA, Sanofi, World Medicine, etc.

Average market prices

Dashboard. Weighted average cost of a pack (WACP) on the pharmaceutical market of Uzbekistan (Source: UPharma Consulting; IQVIA)

The weighted average cost of a pack (WACP) notably decreased in 2017 and 2018 after reaching its highest value in 2016 – USD 3.21 per pack. In 9M 2019, WACP in the total market amounted to USD 1.63, growing by 12.4% YoY vs 9M 2018.

The pre-crisis level was still far from reaching. Therefore, local companies had favorable conditions as demand for cheaper pharma products increased, while incomes of foreign companies in USD notably fell.

Purchase the Full report

Other reports from the series

Let's stay in touch

"UPharma Consulting"
Holosiivskiy avenue, 30B
office 58
Kyiv, 03039

Telephone: + 380 (97) 953 68 14